When did CYCLERION THERAPEUTICS INC (CYCN) report earnings last quarter?
CYCLERION THERAPEUTICS INC (CYCN) last reported earnings on 3/2/2026.
NASDAQ:CYCN • US23255M2044
Past quarterly earnings results for CYCLERION THERAPEUTICS INC (CYCN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.30 | - | - | 880K | - | 353.61% | ||
| Q2 2025 | -0.11 | - | - | 90K | - | - | ||
| Q1 2025 | - | - | 81K | - | - | |||
| Q4 2024 | - | - | 1.806M | - | - | |||
| Q3 2024 | - | - | 194K | - | - | |||
| Q2 2024 | - | - | - | - | ||||
| Q4 2023 | -0.41 | - | -42.86% | - | -100.00% | |||
| Q3 2023 | -0.93 | -0.34 | -176.29% | 80.62% | - | - | ||
| Q2 2023 | -0.29 | - | 95.39% | - | 100.00% | |||
| Q1 2023 | -0.30 | - | 95.07% | - | -100.00% | |||
| Q4 2022 | -0.29 | - | 95.67% | 610K | - | 15.09% | ||
| Q3 2022 | -4.80 | -6.32 | 24.10% | 7.69% | 156.06K | -100.00% | -100.00% | |
| Q2 2022 | -6.20 | -6.12 | -1.31% | - | -410K | 362.61K | -213.07% | -113.67% |
| Q1 2022 | -6.00 | -7.34 | 18.30% | - | 710K | 561K | 26.56% | 1,083.33% |
| Q4 2021 | -6.60 | -6.12 | -7.84% | 38.89% | 530K | 918K | -42.27% | 307.69% |
| Q3 2021 | -5.20 | -7.24 | 28.20% | 61.76% | 350K | 1.53M | -77.12% | -12.50% |
| Q2 2021 | - | - | 3M | - | 300.00% | |||
| Q1 2021 | - | - | 60K | - | -94.06% | |||
| Q4 2020 | -10.80 | -3.92 | -175.74% | - | 130K | - | - | |
| Q3 2020 | -13.60 | -11.51 | -18.20% | - | 400K | - | - | |
| Q2 2020 | -14.00 | -17.61 | 20.48% | - | 750K | - | - | |
| Q1 2020 | -14.60 | -17.73 | 17.64% | - | 1.01M | - | - |
Notes
CYCLERION THERAPEUTICS INC (CYCN) last reported earnings on 3/2/2026.
CYCLERION THERAPEUTICS INC (CYCN) missed EPS estimates and missed revenue estimates in the most recent quarter.